Investing.com - IDEXX Labs (NASDAQ: IDXX) reported second quarter EPS of $2.44, $0.45 worse than the analyst estimate of $2.89. Revenue for the quarter came in at $1B versus the consensus estimate of $1.01B.
Guidance
IDEXX Labs sees FY 2024 EPS of $10.31-$10.59 versus the analyst consensus of $11.01.
IDEXX Labs sees FY 2024 revenue of $3.89B-$3.95B versus the analyst consensus of $3.94B.
IDEXX Labs's stock price closed at $455.08. It is down -9.13% in the last 3 months and down -10.48% in the last 12 months.
IDEXX Labs saw 2 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See IDEXX Labs's stock price’s past reactions to earnings here.
According to InvestingPro, IDEXX Labs's Financial Health score is "great performance".
Check out IDEXX Labs's recent earnings performance, and IDEXX Labs's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar